Skip to main content
Top
Published in: Clinical Journal of Gastroenterology 1/2021

01-02-2021 | Magnetic Resonance Imaging | Case Report

Two case reports of brain metastases in patients with pancreatobiliary neuroendocrine carcinoma

Authors: Takaaki Furukawa, Takashi Sasaki, Tsuyoshi Takeda, Takafumi Mie, Ryo Kanata, Akiyoshi Kasuga, Masato Matsuyama, Masato Ozaka, Naoki Sasahira

Published in: Clinical Journal of Gastroenterology | Issue 1/2021

Login to get access

Abstract

Brain metastases are extremely rare in patients with pancreatobiliary neuroendocrine caricnoma (PB-NEC). In this case report, we report two rare cases of brain metastases in patients with PB-NEC. Each patient was diagnosed with brain metastases five and ten months after the initial diagnosis of PB-NEC. It is noteworthy that the serum tumor marker neuron-specific enolase (NSE) or pro-gastrin-releasing peptide (Pro-GRP) was elevated, although the primary and metastatic lesions other than in the brain were under control with systemic chemotherapy. Moreover, the patients complained of no neurological symptoms until they were diagnosed with brain metastases. Although the incidence of brain metastases of PB-NEC is exceedingly low, it is important to keep in mind the possibility of brain metastases during the course of treatment for PB-NEC. In addition, we discuss a strategy of treatment and screening for brain metastases of PB-NEC in this case report.
Literature
1.
go back to reference Sasaki T, Takamatsu M, Furukawa T, et al. Clinicopathological analysis of biliary neuroendocrine neoplasms and chemotherapy for biliary neuroendocrine carcinoma. Tando. 2020;34:153–62. Sasaki T, Takamatsu M, Furukawa T, et al. Clinicopathological analysis of biliary neuroendocrine neoplasms and chemotherapy for biliary neuroendocrine carcinoma. Tando. 2020;34:153–62.
2.
go back to reference Korse CM, Taal BG, van Velthuysen ML, et al. Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry. Eur J Cancer. 2013;49:1975–83.CrossRef Korse CM, Taal BG, van Velthuysen ML, et al. Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry. Eur J Cancer. 2013;49:1975–83.CrossRef
3.
go back to reference Kang H, O’Connell JB, Leonardi MJ, et al. Rare tumors of the colon and rectum: a national review. Int J Colorectal Dis. 2007;22:183–9.CrossRef Kang H, O’Connell JB, Leonardi MJ, et al. Rare tumors of the colon and rectum: a national review. Int J Colorectal Dis. 2007;22:183–9.CrossRef
4.
go back to reference Boyar Cetinkaya R, Aagnes B, Thiis-Evensen E, et al. Trends in incidence of neuroendocrine neoplasms in Norway: a report of 16,075 cases from 1993 through 2010. Neuroendocrinology. 2017;104:1–10.CrossRef Boyar Cetinkaya R, Aagnes B, Thiis-Evensen E, et al. Trends in incidence of neuroendocrine neoplasms in Norway: a report of 16,075 cases from 1993 through 2010. Neuroendocrinology. 2017;104:1–10.CrossRef
5.
go back to reference Ito T, Igarashi H, Nakamura K, et al. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: A nationwide survey analysis. J Gastroenterol. 2015;50:58–64.CrossRef Ito T, Igarashi H, Nakamura K, et al. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: A nationwide survey analysis. J Gastroenterol. 2015;50:58–64.CrossRef
6.
go back to reference Fujii M, Saito H, Shiode J. Rare case of a gallbladder neuroendocrine carcinoma. Clin J Gastroenterol. 2019;12:38–45.CrossRef Fujii M, Saito H, Shiode J. Rare case of a gallbladder neuroendocrine carcinoma. Clin J Gastroenterol. 2019;12:38–45.CrossRef
7.
go back to reference Modlin IM, Shapiro MD, Kidd M. An analysis of rare carcinoid tumors: clarifying these clinical conundrums. World J Surg. 2005;29:92–101.CrossRef Modlin IM, Shapiro MD, Kidd M. An analysis of rare carcinoid tumors: clarifying these clinical conundrums. World J Surg. 2005;29:92–101.CrossRef
8.
go back to reference Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.CrossRef Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.CrossRef
9.
go back to reference Chen C, Wang L, Liu X, et al. Gallbladder neuroendocrine carcinoma: report of 10 cases and comparision of clinicopathologic features with gallbladder adenocarcinoma. Int J Clin Exp Pathol. 2015;8:8218–26.PubMedPubMedCentral Chen C, Wang L, Liu X, et al. Gallbladder neuroendocrine carcinoma: report of 10 cases and comparision of clinicopathologic features with gallbladder adenocarcinoma. Int J Clin Exp Pathol. 2015;8:8218–26.PubMedPubMedCentral
10.
go back to reference Garcia Carbonero R, Sorbye H, Baudin E, et al. ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology. 2016;103:186–94.CrossRef Garcia Carbonero R, Sorbye H, Baudin E, et al. ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology. 2016;103:186–94.CrossRef
11.
go back to reference Soffietti R, Abacioglu U, Baumert B, et al. Diagnosis and treatment of brain metastases from solid tumors: Guidelines from the European Association of Neuro-Oncology (EANO). Neuro Oncol. 2017;19:162–74.CrossRef Soffietti R, Abacioglu U, Baumert B, et al. Diagnosis and treatment of brain metastases from solid tumors: Guidelines from the European Association of Neuro-Oncology (EANO). Neuro Oncol. 2017;19:162–74.CrossRef
12.
go back to reference Kotecha R, Zimmerman A, Murphy ES, et al. Management of brain metastasis in patients with pulmonary neuroendocrine carcinomas. Technol Cancer Res Treat. 2016;15:566–72.CrossRef Kotecha R, Zimmerman A, Murphy ES, et al. Management of brain metastasis in patients with pulmonary neuroendocrine carcinomas. Technol Cancer Res Treat. 2016;15:566–72.CrossRef
13.
go back to reference Prayongrat A, Tao R, Allen PK, et al. Outcomes of stereotactic radiosurgery of brain metastases from neuroendocrine tumors. Neurooncol Pract. 2018;5:37–45.PubMed Prayongrat A, Tao R, Allen PK, et al. Outcomes of stereotactic radiosurgery of brain metastases from neuroendocrine tumors. Neurooncol Pract. 2018;5:37–45.PubMed
14.
go back to reference Reveiz L, Rueda JR, Cardona AF. Chemotherapy for brain metastases from small cell lung cancer. Cochrane Database Syst Rev. 2012;6:CD007464. Reveiz L, Rueda JR, Cardona AF. Chemotherapy for brain metastases from small cell lung cancer. Cochrane Database Syst Rev. 2012;6:CD007464.
15.
go back to reference Franchino F, Rudà R, Soffietti R. Mechanisms and therapy for cancer metastasis to the brain. Front Oncol. 2018;8:161.CrossRef Franchino F, Rudà R, Soffietti R. Mechanisms and therapy for cancer metastasis to the brain. Front Oncol. 2018;8:161.CrossRef
16.
go back to reference Kamath SD, Kumthekar PU. Immune checkpoint inhibitors for the treatment of central nervous system (CNS) metastatic disease. Front Oncol. 2018;8:414.CrossRef Kamath SD, Kumthekar PU. Immune checkpoint inhibitors for the treatment of central nervous system (CNS) metastatic disease. Front Oncol. 2018;8:414.CrossRef
17.
go back to reference Yu LY, Tang J, Zhang CM, et al. New immunotherapy strategies in breast cancer. Int J Environ Res Public Health. 2017;14:68.CrossRef Yu LY, Tang J, Zhang CM, et al. New immunotherapy strategies in breast cancer. Int J Environ Res Public Health. 2017;14:68.CrossRef
18.
go back to reference Farber SH, Tsvankin V, Narloch JL, et al. Embracing rejection: immunologic trends in brain metastasis. Oncoimmunology. 2016;5:e1172153.CrossRef Farber SH, Tsvankin V, Narloch JL, et al. Embracing rejection: immunologic trends in brain metastasis. Oncoimmunology. 2016;5:e1172153.CrossRef
19.
go back to reference Johanns T, Waqar SN, Morgensztern D. Immune checkpoint inhibition in patients with brain metastases. Ann Transl Med. 2016;4(Suppl 1):S9.CrossRef Johanns T, Waqar SN, Morgensztern D. Immune checkpoint inhibition in patients with brain metastases. Ann Transl Med. 2016;4(Suppl 1):S9.CrossRef
20.
go back to reference Leal T, Chang JE, Mehta M, et al. Leptomeningeal metastasis: challenges in diagnosis and treatment. Curr Cancer Ther Rev. 2011;7:319–27.CrossRef Leal T, Chang JE, Mehta M, et al. Leptomeningeal metastasis: challenges in diagnosis and treatment. Curr Cancer Ther Rev. 2011;7:319–27.CrossRef
21.
go back to reference Venur VA, Ahluwalia MS. Novel therapeutic agents in the management of brain metastases. Curr Opin Oncol. 2017;29:395–9.CrossRef Venur VA, Ahluwalia MS. Novel therapeutic agents in the management of brain metastases. Curr Opin Oncol. 2017;29:395–9.CrossRef
22.
go back to reference Lin NU. Targeted therapies in brain metastases. Curr Treat Options Neurol. 2014;16:276.CrossRef Lin NU. Targeted therapies in brain metastases. Curr Treat Options Neurol. 2014;16:276.CrossRef
23.
go back to reference Lin J, Jandial R, Nesbit A, et al. Current and emerging treatments for brain metastases. Oncology (Williston Park). 2015;29:250–7. Lin J, Jandial R, Nesbit A, et al. Current and emerging treatments for brain metastases. Oncology (Williston Park). 2015;29:250–7.
24.
go back to reference Soffietti R, Trevisan E, Rudà R. Targeted therapy in brain metastasis. Curr Opin Oncol. 2012;24:679–86.CrossRef Soffietti R, Trevisan E, Rudà R. Targeted therapy in brain metastasis. Curr Opin Oncol. 2012;24:679–86.CrossRef
25.
go back to reference Esmaeilzadeh M, Majlesara A, Faridar A, et al. Brain metastasis from gastrointestinal cancers: a systematic review. Int J Clin Pract. 2014;68:890–9.CrossRef Esmaeilzadeh M, Majlesara A, Faridar A, et al. Brain metastasis from gastrointestinal cancers: a systematic review. Int J Clin Pract. 2014;68:890–9.CrossRef
27.
go back to reference Krug S, Teupe F, Michl P, et al. Brain metastases in patients with neuroendocrine neoplasms: risk factors and outcome. BMC Cancer. 2019;19:362.CrossRef Krug S, Teupe F, Michl P, et al. Brain metastases in patients with neuroendocrine neoplasms: risk factors and outcome. BMC Cancer. 2019;19:362.CrossRef
Metadata
Title
Two case reports of brain metastases in patients with pancreatobiliary neuroendocrine carcinoma
Authors
Takaaki Furukawa
Takashi Sasaki
Tsuyoshi Takeda
Takafumi Mie
Ryo Kanata
Akiyoshi Kasuga
Masato Matsuyama
Masato Ozaka
Naoki Sasahira
Publication date
01-02-2021
Publisher
Springer Singapore
Published in
Clinical Journal of Gastroenterology / Issue 1/2021
Print ISSN: 1865-7257
Electronic ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-020-01270-w

Other articles of this Issue 1/2021

Clinical Journal of Gastroenterology 1/2021 Go to the issue